Latest period
$2.41M
YoY change
-23.4%
5Y CAGR
-8.6%
Peak year (2020)
$7.53M
Latest annual
$4.81M
Stock-Based Compensation history chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: $4.81M
Stock-Based Compensation growth chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: -23.4%
Stock-Based Compensation history table for Ovid Therapeutics (OVID) from 2014 to 2025
| 2025 | $4.81M | -23.4% | −$1.47M | ||
| 2024 | $6.28M | -13.9% | −$1.01M | ||
| 2023 | $7.29M | +11.1% | +$728.51K | ||
| 2022 | $6.56M | — | +$6.56M | ||
| 2021 | $0.00 | -100.0% | −$7.53M | ||
| 2020 | $7.53M | +44.6% | +$2.32M | ||
| 2019 | $5.21M | -26.3% | −$1.86M | ||
| 2018 | $7.06M | +10.4% | +$666.18K | ||
| 2017 | $6.40M | +75.7% | +$2.76M | ||
| 2016 | $3.64M | +149.9% | +$2.18M | ||
| 2015 | $1.46M | +4304.5% | +$1.42M | ||
| 2014 | $33.09K | — | — |
- 2025$4.81M-23.4%
- 2024$6.28M-13.9%
- 2023$7.29M+11.1%
- 2022$6.56M—
- 2021$0.00-100.0%
- 2020$7.53M+44.6%
- 2019$5.21M-26.3%
- 2018$7.06M+10.4%
- 2017$6.40M+75.7%
- 2016$3.64M+149.9%
- 2015$1.46M+4304.5%
- 2014$33.09K—
Stock-Based Compensation values are taken from Ovid Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Ovid Therapeutics (OVID)
Stock-Based Compensation for Ovid Therapeutics (OVID): headline value $2.41M · YoY -23.4%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Ovid Therapeutics (OVID) reported stock-based compensation of $4.81M – declined 23.4% year-over-year.
Ovid Therapeutics stock-based compensation compound annual growth for the 2020–2025 (5 years) window is -8.6%, with a net decline across the window.
2020 marks the peak stock-based compensation at $7.53M, with the historical low of $0.00 recorded in 2021.
Ovid Therapeutics Stock-Based Compensation by Year
Ovid Therapeutics Stock-Based Compensation 2025: $4.81M
In 2025, Ovid Therapeutics reported stock-based compensation of $4.81M, declined 23.4% below 2024.
Ovid Therapeutics Stock-Based Compensation 2024: $6.28M
Ovid Therapeutics stock-based compensation in 2024 was $6.28M, declined 13.9% below 2023.
Ovid Therapeutics Stock-Based Compensation 2023: $7.29M
2023's stock-based compensation for Ovid Therapeutics came in at $7.29M, grew 11.1% from 2022.
Ovid Therapeutics Stock-Based Compensation 2022: $6.56M
Ovid Therapeutics stock-based compensation in 2022 was $6.56M.
Ovid Therapeutics Stock-Based Compensation 2021: $0.00
Ovid Therapeutics stock-based compensation in 2021 was $0.00.
See more financial history for Ovid Therapeutics (OVID).
Sector peers by Stock-Based Compensation
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation